State Street
ROIV icon

State Street’s Roivant Sciences ROIV Stock Holding History

State Street’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$630M Buy
17,795,975
+1,609,362
+10% +$47.6M 0.02% 524
2026
Q1 		$448M Sell
16,186,613
-1,174,852
-7% -$30.2M 0.02% 584
2025
Q4 		$377M Sell
17,361,465
-1,338,679
-7% -$26.4M 0.01% 647
2025
Q3 		$283M Sell
18,700,144
-1,073,336
-5% -$13.3M 0.01% 771
2025
Q2 		$223M Buy
19,773,480
+911,827
+5% +$9.88M 0.01% 830
2025
Q1 		$190M Sell
18,861,653
-1,940,059
-9% -$21M 0.01% 916
2024
Q4 		$246M Buy
20,801,712
+1,240,463
+6% +$14.7M 0.01% 814
2024
Q3 		$226M Buy
19,561,249
+1,118,561
+6% +$12.7M 0.01% 841
2024
Q2 		$195M Buy
18,442,688
+1,289,554
+8% +$14.1M 0.01% 869
2024
Q1 		$181M Buy
17,153,134
+3,425,716
+25% +$36.9M 0.01% 923
2023
Q4 		$154M Buy
13,727,418
+3,406,626
+33% +$33.2M 0.01% 1007
2023
Q3 		$121M Buy
10,320,792
+786,896
+8% +$8.9M 0.01% 1059
2023
Q2 		$96.1M Buy
9,533,896
+1,500,944
+19% +$13.4M 0.01% 1248
2023
Q1 		$59.3M Buy
8,032,952
+4,525,910
+129% +$37.3M ﹤0.01% 1534
2022
Q4 		$28M Buy
3,507,042
+2,601,911
+287% +$14.5M ﹤0.01% 2007
2022
Q3 		$2.92M Sell
905,131
-191,775
-17% -$742K ﹤0.01% 3298
2022
Q2 		$4.46M Buy
1,096,906
+649,000
+145% +$2.58M ﹤0.01% 3151
2022
Q1 		$2.21M Buy
447,906
+156,106
+53% +$1.03M ﹤0.01% 3522
2021
Q4 		$2.94M Buy
+291,800
New +$2.43M ﹤0.01% 3499

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street's ROIV Position: Q2 2026 in Review

State Street increased its Roivant Sciences (ROIV) stake by 9.9% in Q2 2026, buying an estimated $47.6M and bringing the position to 17,795,975 shares worth $630M. The position accounts for 0.02% of the portfolio, ranked #524.

State Street first reported a position in ROIV in Q4 2021 and has held it in 19 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • State Street held 17,795,975 shares of Roivant Sciences worth $630M as of Q2 2026.
  • State Street bought 1,609,362 Roivant Sciences shares in Q2 2026, an estimated $47.6M.
  • Roivant Sciences made up 0.02% of State Street's portfolio in Q2 2026, its #524 holding.
  • State Street first reported a position in Roivant Sciences in Q4 2021 and has held it in 19 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.